← The Wire
CTNMNasdaq
Contineum Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1855175
Contineum Therapeutics pioneers differentiated small molecule therapies for neurological and inflammatory indications with unmet needs
$444M
Market cap
$15.00
Last close
+5.7%
1D
+29.1%
5D
449K
Volume
Price · last 39 sessions+6.0%
May 4L $11.30 · H $15.00Jun 29
46
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 26, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KReg FD Disclosure · Company UpdateApr 30, 2026424B5424B5Mar 5, 202610-K10-KMar 5, 20268-KResults of Operations · Company UpdateMar 5, 20268-KExecutive ChangeJan 26, 20268-KMaterial Agreement · Company UpdateDec 15, 2025424B5FORM 424B5Dec 12, 2025424B5FORM 424B5Dec 11, 20258-KCompany UpdateDec 11, 20258-KCompany UpdateNov 20, 202510-QFORM 10-QOct 30, 20258-KResults of OperationsOct 30, 20258-KReg FD Disclosure · Company UpdateSep 18, 202510-QFORM 10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KShareholder VoteJun 26, 20258-KResults of Operations · Company UpdateMay 14, 202510-QFORM 10-QMay 14, 2025DEFA14AFORM DEFA14AApr 29, 2025DEF 14AFORM DEF 14AApr 29, 20258-KCompany UpdateApr 28, 20258-KExecutive ChangeMar 17, 202510-KFORM 10-KMar 6, 20258-KResults of OperationsMar 6, 2025SC 13GSC 13GNov 14, 202410-QFORM 10-QNov 6, 20248-KResults of OperationsNov 6, 202410-QFORM 10-QAug 14, 20248-K/AResults of Operations · Reg FD DisclosureAug 14, 20248-KResults of OperationsAug 13, 20248-KExecutive ChangeJun 24, 20248-KExecutive ChangeMay 31, 20248-KExecutive ChangeMay 20, 202410-QFORM 10-QMay 16, 20248-KResults of OperationsMay 16, 2024SC 13GSC 13GApr 15, 2024SC 13GSC 13GApr 15, 20248-KBylaw AmendmentApr 9, 2024424B4424B4Apr 8, 2024S-1/AS-1/AApr 1, 2024S-1S-1Mar 15, 2024
Insider Activity
In the 90 days to Mar 2, 2026: 3 sold $627K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 4,170 | $15.01 | $63K |
| Mar 2, 2026 | Watkins TimCMO & Head of Development | Sell | 3,611 | $15.02 | $54K |
| Feb 25, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 3,824 | $16.01 | $61K |
| Feb 25, 2026 | Stengone Carmine N.CEO and President | Sell | 2,700 | $16.02 | $43K |
| Feb 24, 2026 | Stengone Carmine N.CEO and President | Sell | 4,400 | $16.02 | $70K |
| Feb 24, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 4,300 | $16.03 | $69K |
| Feb 19, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 100 | $16.00 | $2K |
| Feb 11, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 400 | $16.00 | $6K |
| Feb 11, 2026 | Stengone Carmine N.CEO and President | Sell | 400 | $16.00 | $6K |
| Feb 3, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 3,000 | $14.82 | $44K |
| Feb 3, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 1,170 | $15.25 | $18K |
| Jan 28, 2026 | Watkins TimCMO & Head of Development | Sell | 2,800 | $14.09 | $39K |
| Jan 28, 2026 | Watkins TimCMO & Head of Development | Sell | 811 | $14.48 | $12K |
| Jan 5, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 3,670 | $10.35 | $38K |
| Jan 5, 2026 | Lorrain Daniel S.Chief Scientific Officer | Sell | 500 | $11.13 | $6K |
| Dec 29, 2025 | Watkins TimCMO & Head of Development | Sell | 3,611 | $12.06 | $44K |
| Dec 23, 2025 | Lorrain Daniel S.Chief Scientific Officer | Sell | 4,170 | $12.23 | $51K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance